Connect with us

News

Rebiotix, C. Diff Foundation Commend State of Minnesota for Declaring November Clostridium difficile Awareness Month

gbafNews28

Rebiotix Inc, a late-stage biotechnology focused on harnessing the power of the microbiome to treat debilitating diseases, joined the C. Diff Foundation today to congratulate the State of Minnesota for declaring November Clostridium difficile Awareness Month. Rebiotix, part of the Ferring Pharmaceuticals Group, and the C. Diff Foundation indicated that the proclamation approved by the office of Governor Mark Dayton serves to heighten awareness of the impact this disease has on patients in Minnesota and across the United States. The infection, which has been labelled an urgent national health threat by the Centers for Disease Control (CDC), results in 500,000 infections each year and is directly responsible for more than 29,000 deaths annually.

Clostridium difficile infection is recognized as the number one healthcare associated infection in the U.S., says Lee Jones, president and CEO of Rebiotix. Its a debilitating, isolating, and potentially life-threatening condition. We applaud both the C. Diff Foundation and Governor Daytons administration for bringing awareness to this significant health concern, and look forward to continuing to develop novel therapies to address this unmet need.

Rebiotixs first product, RBX2660, is currently in a Phase 3 clinical trial for the prevention of recurrent Clostridium difficile infection. It is the most clinically advanced product of the companys Microbiota Restoration Therapy„¢ drug platform. The second product, known as RBX7455, a lyophilized, non-frozen, room-temperature stable oral formulation, was recently studied in a Phase 1 investigator-sponsored trial for recurrent Clostridium difficile infection.

Supporting C. diff patients, their families, and the providers who care for them requires leadership across all fields “ from governmental institutions, to advocacy, to academia and industry, says Nancy Caralla, founder of the C. Diff Foundation. On behalf of C. diff patients, we applaud the efforts of the State of Minnesota and Rebiotix for playing such an important role in raising awareness about CDI. This is a critical part to reducing the impact and rate of the infection everywhere.

About Rebiotix Rebiotix Inc, part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track, Orphan and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection. Rebiotixs clinical pipeline also features RBX7455, a lyophilized, room temperature stable oral capsule formulation. Rebiotix is also targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy„¢ platform. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.

About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and womens health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the companys research and development investment goes towards finding innovative and personalized healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

About the C Diff Foundation The C Diff Foundation is a non-profit, 501(c)(3) organization established in 2012. It is comprised of 100% volunteering professionals dedicated to supporting public health through education and advocacy for C. difficile infection prevention, treatments, environmental safety and support world-wide. The Foundations CEO and founder is a nurse inspired to create the foundation after witnessing the loss of her father to CDI, as well as suffering from the infection herself. The C Diff Foundation members, with their volunteer patient advocates, successfully raise C. diff awareness locally and in over fifty-six (56) countries and host a U.S. nation-wide hotline (1-844-FOR-CDIF) to support healthcare providers, patients and families through the difficulties of a C. diff infection.

Rebiotix Inc
www.rebiotix.com
Courtney
Jones, 651-705-8774
[email protected]

News

ROSEN, A TOP RANKED FIRM, Reminds Aurora Cannabis Inc. Investors of Important December 1 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ACB

gbafNews28

NEW YORK, Nov. 24, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (2) Aurora's purported “business transformation plan” and cost reset failed to mitigate the foregoing issues; (3) accordingly, it was foreseeable that Aurora would record significant goodwill and asset impairment charges; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 1, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1965.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm's attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-top-ranked-firm-reminds-aurora-cannabis-inc-investors-of-important-december-1-deadline-in-securities-class-action-encourages-investors-with-losses-in-excess-of-100k-to-contact-firm–acb-301180155.html

SOURCE Rosen Law Firm, P.A.

Continue Reading

News

InMed Announces Election of Directors

gbafNews28

VANCOUVER, BC, Nov. 24, 2020 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today confirmed that, at its annual general and special meeting of shareholders held on November 20, 2020 (the “Meeting”), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 7, 2020, were approved by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:

Director

Votes For

Withheld Votes

Number

Percentage

Number

Percentage

Eric A. Adams

639,176

90.84%

64,464

9.16%

Adam Cutler

654,431

93.01%

49,209

6.99%

William J. Garner

644,945

91.66%

58,695

8.34%

Andrew Hull

654,149

92.97%

49,491

7.03%

Catherine Sazdanoff

653,532

92.88%

50,108

7.12%

InMed filed a report of voting results on SEDAR at www.sedar.com on November 24, 2020.

About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: leading the way in the clinical development of CBN; developing a pipeline of cannabinoid-based medications in diseases with high unmet medical need; and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cision View original content:http://www.prnewswire.com/news-releases/inmed-announces-election-of-directors-301180215.html

SOURCE InMed Pharmaceuticals Inc.

Continue Reading

News

Glow Joins Nielsen Connect Partner Network to Accelerate Access to Consumer Insights

gbafNews28

New partnership combines speed of Glow's research tech with Nielsen's industry-leading data to create greater value for researchers

MELBOURNE, Australia, Nov. 25, 2020 /PRNewswire/ — Today, it was announced that Glow, a leading tech platform in global consumer analytics, has joined the Nielsen Connect Partner Network, the data industry's largest open ecosystem of technology-driven solution providers for researchers, corporations and governments.

The new relationship enables Glow's real-time insights platform to support Nielsen's clients around the world. The partnership strengthens Glow as a leading provider of data analytics solutions and the alliance enables an expanded reach for Glow's innovative consumer insights platform.

“The Glow platform was built to supply businesses with real-time consumer data to bring certainty to decision making,” said Tim Clover, Founder and CEO of Glow.

“This new partnership means our online panel of 62 million people, across 45 countries, can be accessed by Nielsen's clients to garner rapid consumer sentiment, which is a valuable tool in the swiftly changing business environments we find ourselves in today.”

Brett Jones, Global Leader, Nielsen Connect Partner Network, said: “The Nielsen Connect Partner Network was formed to enable ongoing innovation, and we are thrilled to add Glow to our growing list of advanced data solution providers. We are excited about Glow's ability to help clients identify consumer trends and intentions in a rapid, nimble way.”

Since launching in 2016, the Nielsen Connect Partner Network has been instrumental in driving business value for more than 175 unique Nielsen clients by simplifying industry collaboration and providing more relevant and accurate results from partners that align to the way clients measure their business.

The Nielsen Connect Partner Network serves both partners and clients by making it easier for collaboration. With barriers removed, clients and partners transition their workload from managing data, to doing things with the data, all within the largest curated network of vendors available.

Existing Nielsen clients can book a Glow demo directly, here.

About Glow: Glow is a data research and analytics firm founded 7 years ago with the central goal of delivering rapid response insights to enable nimble decision making. Glow has made headway in the democratisation of research via a cloud-based platform which empowers business to understand, measure and extract quick turnaround public insights to support evolving organisational needs and objectives.

Glow delivers a specialised customer insights ecosystem, with easy-to-use tools and resources to inform a deep understanding of consumer and client sentiment. Its cost-effective, speed to insights capabilities means Glow is rapidly becoming a leading global research platform used by corporations and SMEs.

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News22 mins ago

GameIQ Spins Up Executive Team and Board of Directors

SAN DIEGO, Nov. 24, 2020 /PRNewswire-PRWeb/ — GameIQ, Inc., the creator and developer of the Spindy app, today announced new...

gbafNews28 gbafNews28
News22 mins ago

Option3Ventures Technology Board Member, Greg Akers, Appointed as Chief Technology Officer of Veracity Industrial Networks

NEW YORK, Nov. 24, 2020 /PRNewswire-PRWeb/ — Option3Ventures (O3V), a leading cybersecurity investment specialist firm, announced today that Greg Akers,...

gbafNews28 gbafNews28
News22 mins ago

Freedonia Analyst Weighs In On West Fraser's Acquisition of Norbord

CLEVELAND, Nov. 24, 2020 /PRNewswire/ — West Fraser Timber Company, a leading supplier of lumber and other wood products extensively...

gbafNews28 gbafNews28
News22 mins ago

8 Ways to Protect Yourself Against Scams on Black Friday and Cyber Monday

SCOTTSDALE, Ariz., Nov. 24, 2020 /PRNewswire-PRWeb/ — The holidays are the most wonderful time of the year, especially for scammers....

gbafNews28 gbafNews28
News22 mins ago

Market America | SHOP.COM Partners With Packsize To Solve Packaging Constraints And Improve Efficiencies While Becoming More Environmentally Friendly

GREENSBORO, N.C., Nov. 24, 2020 /PRNewswire-PRWeb/ — Market America | SHOP.COM, a global product brokerage and internet marketing company that...

gbafNews28 gbafNews28
News22 mins ago

Glow Joins Nielsen Connect Partner Network to Accelerate Access to Consumer Insights

New partnership combines speed of Glow's research tech with Nielsen's industry-leading data to create greater value for researchers MELBOURNE, Australia,...

gbafNews28 gbafNews28
News22 mins ago

InMed Announces Election of Directors

VANCOUVER, BC, Nov. 24, 2020 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company...

gbafNews28 gbafNews28
News22 mins ago

ROSEN, A TOP RANKED FIRM, Reminds Aurora Cannabis Inc. Investors of Important December 1 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ACB

NEW YORK, Nov. 24, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities...

gbafNews28 gbafNews28
News24 mins ago

Fireblocks Raises $30 Million In Series B Funding Led by Paradigm

Fred Ehrsam joins Fireblocks Board of Directors as company looks to aggressively expand its presence in key global markets  ...

gbafNews28 gbafNews28
News24 mins ago

Allianz: Cyber crime brings expensive losses for companies, but internal failures most frequent cause of cyber claims

AGCS analysis of more than 1,700 cyber claims: External events such as “DDoS” attacks result in the most costly cyber...